The B7-H3–Targeting Antibody–Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models
Open Access
- 22 February 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 27 (10), 2938-2946
- https://doi.org/10.1158/1078-0432.ccr-20-4221
Abstract
Purpose:. Patients with relapsed pediatric solid malignancies have few therapeutic options, and many of these patients die of their disease. B7-H3 is an immune checkpoint protein encoded by the CD276 gene that is overexpressed in many pediatric cancers. Here, we investigate the activity of the B7-H3–targeting antibody–drug conjugate (ADC) m276-SL-PBD in pediatric solid malignancy patient-derived (PDX) and cell line–derived xenograft (CDX) models.Experimental Design:. B7-H3 expression was quantified by RNA sequencing and by IHC on pediatric PDX microarrays. We tested the safety and efficacy of m276-SL-PBD in two stages. Randomized trials of m276-SL-PBD of 0.5 mg/kg on days 1, 8, and 15 compared with vehicle were performed in PDX or CDX models of Ewing sarcoma (N = 3), rhabdomyosarcoma (N = 4), Wilms tumors (N = 2), osteosarcoma (N = 5), and neuroblastoma (N = 12). We then performed a single mouse trial in 47 PDX or CDX models using a single 0.5 m/kg dose of m276-SL-PBD.Results:. The vast majority of PDX and CDX samples studied showed intense membranous B7-H3 expression (median H-score 177, SD 52). In the randomized trials, m276-SL-PBD showed a 92.3% response rate, with 61.5% of models showing a maintained complete response (MCR). These data were confirmed in the single mouse trial with an overall response rate of 91.5% and MCR rate of 64.4%. Treatment-related mortality rate was 5.5% with late weight loss observed in a subset of models dosed once a week for 3 weeks.Conclusions:. m276-SL-PBD has significant antitumor activity across a broad panel of pediatric solid tumor PDX models.Keywords
Other Versions
Funding Information
- NCI (U01 CA199287)
- NCI (R35 CA220500)
- NCI (U01 CA199221)
- NCI (NCI U01 CA199297)
- NCI (F31CA239424)
- Giulio D'Angio Endowed Chair
This publication has 49 references indexed in Scilit:
- B7-H3 is Overexpressed in Patients Suffering Osteosarcoma and Associated with Tumor Aggressiveness and MetastasisPLOS ONE, 2013
- Development of an Fc-Enhanced Anti–B7-H3 Monoclonal Antibody with Potent Antitumor ActivityClinical Cancer Research, 2012
- Tissue microarray design and construction for scientific, industrial and diagnostic useJournal of Pathology Informatics, 2012
- B7‐H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis‐associated genesInternational Journal of Cancer, 2011
- The development of pyrrolobenzodiazepines as antitumour agentsExpert Opinion on Investigational Drugs, 2011
- Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastomaJournal of Neuro-Oncology, 2009
- Chronic Disease in the Childhood Cancer Survivor Study Cohort: A Review of Published FindingsJournal of Clinical Oncology, 2009
- Survivors of Childhood Cancer: Coming of AgeHematology/Oncology Clinics of North America, 2008
- Cell killing by antibody–drug conjugatesCancer Letters, 2007
- Tissue microarrays for high-throughput molecular profiling of tumor specimensNature Medicine, 1998